tefibazumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 470478505

| image =

| type = mab

| mab_type = mab

| source = zu/o

| target = Clumping factor A

| tradename = Aurexis

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|CAS}}

| CAS_number = 521079-87-8

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = SBO7Q9G95R

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D06054

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C=6548 | H=10122 | N=1730 | O=2034 | S=44

}}

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis{{ClinicalTrialsGov|NCT00198289|Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs}} and of methicillin-resistant S. aureus.{{cite journal | vauthors = Pan A, Lorenzotti S, Zoncada A | title = Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection | journal = Recent Patents on Anti-Infective Drug Discovery | volume = 3 | issue = 1 | pages = 10–33 | date = January 2008 | pmid = 18221183 | doi = 10.2174/157489108783413173 }}

It was developed by Inhibitex.{{cite journal | vauthors = John JF | title = Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection | journal = Current Opinion in Molecular Therapeutics | volume = 8 | issue = 5 | pages = 455–60 | date = October 2006 | pmid = 17078388 }}